Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : National Institute on Drug Abuse
Deal Size : $0.2 million
Deal Type : Funding
EpiVario Awarded SBIR Grant from NIH to Develop Treatments for Opioid Use Disorder
Details : The grant will be used to advance the company's research towards developing a novel epigenetic regulator as a treatment for opioid use disorder (OUD).
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 01, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : National Institute on Drug Abuse
Deal Size : $0.2 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?